Halozyme Therapeutics, Inc.: financial statements

HALONASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$91.35

November 20, 2026Market cap $10.8B

What Ploutos Investor adds for Halozyme Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 26% since Nov 5, 2026, when the 10-Q these figures come from was filed ($122.96 then, $91.35 on Nov 20, 2026). The figures date from before that move.10-Q

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+29.8% a year over 2 years

Line202320242025Average a year
Revenue $829M$1.0B$1.4B+29.8%
Cost of revenue $192M$159M$229M+9.0%
Gross profit $637M$856M$1.2B+35.4%
Operating income $338M$551M$469M+17.9%
Net income $282M$444M$317M+6.1%
Earnings per share $2.10$3.43$2.56+10.4%
Earnings per share, basic $2.13$3.50$2.64+11.3%
Margins
Gross margin 76.8%84.3%83.6%
Operating margin 40.7%54.3%33.6%
Net margin 34.0%43.7%22.7%

Financial statements

HALO's revenue, profits and cash flows from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$233M Due within 2 years$35M Leases32.1% Effective tax rate

When the debt falls due

Dec 31, 2025

Due within 2 years

$233M

Total falling due

$2.2B

Total in the ladder $2.2B, from the annual report dated December 31, 2025. Principal of loans and bonds, without leases and interest. The filing

  • 2026: $12M
  • 2027: $221M
  • 2028: $481M
  • 2029: $6.6M
  • 2030: $6.6M
  • 2031 on: $1.5B

The ladder at each year end

Year1 yr2 yrs3 yrs4 yrs5 yrsLater
2025$12M$221M$481M$6.6M$6.6M$1.5B
2024$9.2M$9.2M$813M$724M$0$0
2023$9.2M$9.2M$9.2M$813M$724M$0

The ladder at each year end

When HALO's debt fell due, as each annual report set it out, from 2013 to 2022, 10 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Leases

Dec 31, 2025

Operating leases

$35M

Finance leases

–

Lease cost for the year
$8.7M

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Operating lease payments by year

Lease liability by year

Leases

HALO's leases from 2018 to 2022, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Goodwill by segment

Dec 31, 2025

Total goodwill

$580M

The company does not state its goodwill by segment, at December 31, 2025. The filing

Goodwill by year

Goodwill by year

HALO's goodwill from 2021 to 2022, 2 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

32.1%

+11.1 pts

The company paid 32.1% in tax on its profit, 11.1 points above the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Non-deductible expenses

+14.0 pts

State and local taxes

+2.8 pts

FDII deduction

-4.9 pts

Smaller lines (4)

-0.8 pts

Effective rate

32.1%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

Effective tax rate by year

The tax rate HALO paid on its profit, from 2014 to 2022, 9 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Where the change in earnings per share came from

Diluted earnings per share went from $3.43 in the fiscal year to Dec 31, 2024 to $2.56 in the year to Dec 31, 2025, a change of -$0.87.

Measured by size, 21.6% of the movement came from outside sales and operating margin: interest and other items, the tax rate, what went to others and the share count.

+$0.98
-$1.45
-$0.05
-$0.49
+$0.13

Earnings per share is split as sales times operating margin, plus interest and other items, after tax, times the part that goes to the common shareholders, divided by the diluted share count. Each source's part is its average effect over every order in which the six can change, so the parts add up exactly to the change. From the annual reports; net income over the diluted count matches the earnings per share the company filed within 2%.

Receivables and inventory against sales

In the quarter to Sep 30, 2026, sales were +39.2% on the same quarter a year earlier, and receivables +51.0%. Inventory was -28.6%, against +49.3% for the cost of sales.

a year earlier 88 days
96 days
a year earlier 306 days
146 days

Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Taxes: deferred and paid

The deferred part was -3.0% of the tax charge in the year to Dec 31, 2025. The rows show the last 3 years.

Cash taxes paid were 87.2% of the current tax charge in the year to Dec 31, 2025.

Deferred share, year to Dec 31, 2025-$4.5M of $150M
-3.0%
Deferred share, year to Dec 31, 2024$1.1M of $113M
1.0%
Deferred share, year to Dec 31, 2023$36M of $67M
54.0%
$135M paid, $154M current
87.2%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Halozyme Therapeutics's filings show?

These are Halozyme Therapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about HALO's financials

Didn't find what you were looking for?

Ask us
How much revenue did HALO have in 2025?

Halozyme Therapeutics had revenue of $1.4B and net income of $317M in fiscal 2025, a net margin of 22.7%.

How much debt does HALO have?

On December 31, 2025 Halozyme Therapeutics had total assets of $2.5B, debt of $2.1B and shareholders' equity of $49M.

How much free cash flow does HALO have?

In fiscal 2025 Halozyme Therapeutics had cash from operations of $652M and spent $7.0M on capital expenditure, leaving $645M of free cash flow.

Where are the figures from?

From Halozyme Therapeutics, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.